Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarextumab - OncoMed Pharmaceuticals

Next Previous
Search
Drug Profile

Tarextumab - OncoMed Pharmaceuticals

Alternative Names: Anti-Notch 2/3; Anti-Notch 2/3 monoclonal antibody; OMP-59R5; TRXT

Latest Information Update: 25 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Notch-2 receptor antagonists; Notch-3 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
  • 17 Apr 2017 Top-line results from the phase Ib/II PINNACLE trial in Small cell lung cancer released by OncoMed Pharmaceuticals
  • 05 Apr 2017 Pharmacodynamics data from the phase Ib/II PINNACLE trial in Small cell lung cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top